Clinical trials: Intervertebral Disc Degeneration
Degenerative Disc Disease
Trinity Evolution in Anterior Cervical Disectomy and Fusion (ACDF)
The purpose of this study is to utilize Trinity Evolution in conjunction with an interbody spacer and supplemental anterior fixation of the surgeon's choice and to follow the patients to measure the clinical outcomes and rate of…
- Trial name
- NCT00951938
- Where
- 13 sites in United States
- Volunteers
- 200 people
- Sponsor
- Orthofix Inc.
Lumbar Degenerative Disc Disease
CARES Lumbar Artificial Disc Registry
The purpose of the registry is to assess outcomes following treatment with lumbar total disc replacement (TDR) in patients outside the clinical trial setting.
- Trial name
- NCT02139527
- Testing
- Total Disc Replacement
- Volunteers
- 120 people
- Sponsor
- DePuy Spine
Degenerative Disc Disease
Pivotal Study of rhBMP-2/ACS/LT-CAGE® Device for Anterior Lumbar Interbody Fusion in Patients With Symptomatic Degenerative Disc Disease
This study is designed to assess the safety and effectiveness of the rhBMP-2/ACS/LT-CAGE® device as compared to the LT-CAGE® device with autogenous bone in patients with symptomatic degenerative disc disease using an open…
- Trial name
- NCT01491386
- Testing
- rhBMP-2/ACS/LT-CAGE® Device, Autogenous Bone/LT-CAGE® Device
- Volunteers
- 279 people
- Sponsor
- Medtronic Spinal and Biologics
Degenerative Disc Disease, Spondylolisthesis
Post-market Surveillance Study of FLXfit™ TLIF Interbody Fusion Device
This study is a post-market clinical follow-up study. A post-market, prospective clinical trial will be conducted. The data collected from this study will serve the purpose of confirming safety and performance of the FLXfit™…
- Conditions
- Degenerative Disc Disease, Spondylolisthesis, Retrolisthesis
- Trial name
- FLXFit (NCT02805985)
- Testing
- FLXfit™ TLIF Interbody Fusion Device
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Expanding Orthopedics Ltd.
Degenerative Spondylolisthesis
Safety Evaluation of ART352-L in Subjects Undergoing Posterolateral Spinal Fusion
Ankasa Regenerative Therapeutics, Inc. (Ankasa) is developing ART352-L, a liposomal formulation of recombinant human Wnt3A protein, that is applied ex vivo, to harvested autologous bone grafts (autograft) to enhance the…
- Trial name
- NCT04378543
- Testing
- ART352-L
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Ankasa Regenerative Therapeutics, Inc.